HRS-7450

Unknown / undisclosed

Phase 2Mechanism not established

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Acute Ischemic Stroke
NCT07233070 · Fujian Shengdi Pharmaceutical Co., Ltd.
2025-10-31 – 2026-09-17 · Acute Ischemic Stroke
What this study did
Phase 1 (2)
Acute Ischemic Stroke
Other / comorbidity
NCT06087094 · Fujian Shengdi Pharmaceutical Co., Ltd.
2023-10 – 2023-12 · Cerebral Stroke
What this study did

Competitive landscape

This drug's own stage for Acute Ischemic Stroke: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HRS-7450: this drugPhase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Ticagrelor (Brilinta)ApprovedSmall moleculeP2Y12 receptorReliable signal
NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants
Edaravone (TTYP01)Phase 3Small moleculeoxidative stressnot yet gradedNo reviewed efficacy summary in this indication
Rinvecalinase AlfaPhase 2/3Protein / enzyme therapeuticTissue kallikrein-1 (KLK1)not yet gradedNo reviewed efficacy summary in this indication
Apadamtase Alfa (Adzynma)Phase 2Protein / enzyme therapeuticADAMTS13not yet gradedNo reviewed efficacy summary in this indication
HRS-4029Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
HRS-8829
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.